Competition: An Antidote To The High Price Of Prescription Drugs
Open Access
- 1 July 2004
- journal article
- Published by Health Affairs (Project Hope) in Health Affairs
- Vol. 23 (4) , 151-158
- https://doi.org/10.1377/hlthaff.23.4.151
Abstract
Patent protection and factors unique to prescription drugs weaken the forces keeping prices near costs for other products. A growing public consensus that affordable drugs should be available to all is likely to increase the upward pressure on prices. To restore competition to all parts of the pharmaceutical industry, we propose a new institute at the National Institutes of Health that would compete with the private sector for pharmaceutical intellectual property by establishing competition for research and development contracts open to public and private institutions; retain the resulting patents; and grant cost-free, nonexclusive licenses to all qualified producers.Keywords
This publication has 5 references indexed in Scilit:
- Increasing use of new prescription drugs: a case study.Health Affairs, 2000
- Estimating allocative inefficiency in the prescription drug industryApplied Economics Letters, 1997
- Haggling for a Patent: What a Government Would Have to Pay for Prescription Drug PatentsHealth Economics, 1997
- Longer Patents for Increased Generic Competition in the USPharmacoEconomics, 1996
- Pricing, Profits, and Technological Progress in the Pharmaceutical IndustryJournal of Economic Perspectives, 1993